Skip to main content
Premium Trial:

Request an Annual Quote

BioSeek Extends Merck Profiling Plan to 2012

NEW YORK (GenomeWeb News) – BioSeek has extended an agreement with Merck Serono, under which it will continue to profile compounds for the drug developer for another three years, BioSeek said today.

The new agreement extends a previous compound profiling plan from 2008, which had BioSeek using its BioMap platform to evaluate small molecule compounds and proteins in different therapeutic areas. The BioMap Systems use cell-based human disease models to develop information about potential drugs that companies can use to help choose and develop candidates.

The research agreement, which will last until 2012, includes studies that will support target differentiation, lead selection, and nomination of candidates that may be developed by Merck Serono, which is a division of Darmstadt, Germany-based Merck KGaA.

Financial terms of the agreement were not released.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.